155 related articles for article (PubMed ID: 2669981)
1. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
[TBL] [Abstract][Full Text] [Related]
2. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
[TBL] [Abstract][Full Text] [Related]
3. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
Gattaz WF; Rost W; Hübner CK; Bauer K
Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
[TBL] [Abstract][Full Text] [Related]
4. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol plasma levels and dose optimization.
Coryell W; Miller DD; Perry PJ
Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of determination of plasma haloperidol levels.
Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
[TBL] [Abstract][Full Text] [Related]
7. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Van Putten T; Marder SR; Mintz J; Poland RE
Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
10. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
11. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
Hollister LE; Kim DY
Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
[TBL] [Abstract][Full Text] [Related]
12. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
13. Correlates of rapid neuroleptic response in male patients with schizophrenia.
Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
[TBL] [Abstract][Full Text] [Related]
14. The relationship between plasma haloperidol concentrations and clinical results.
Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
[No Abstract] [Full Text] [Related]
15. Haloperidol plasma levels and acute clinical change in schizophrenia.
Coryell W; Kelly M; Perry PJ; Miller DD
J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709
[TBL] [Abstract][Full Text] [Related]
16. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
[TBL] [Abstract][Full Text] [Related]
18. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
19. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
[TBL] [Abstract][Full Text] [Related]
20. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
Arvanitis LA; Miller BG
Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
